GlaxoSmithKline Consumer Healthcare Pakistan : Lifting of Force Majeure - Panadol Tablets, Panadol Extra Tablets and Children s Panadol Liquid Range

4 November 2022

Deputy General Manager

Pakistan Stock Exchange Limited

Stock Exchange Building,

Stock Exchange Road,

Karachi.

Subject:	Disclosure of Material Information - Lifting of Force Majeure - Panadol Tablets,
	Panadol Extra Tablets and Children's Panadol Liquid Range

Dear Sir / Madam,

This is with reference to section 96 of the Securities Act 2015 and Clause 5.6.1(a) of PSX Limited Regulations. The Company hereby conveys the following material information:

Please be notified that GlaxoSmithKline Consumer Healthcare Pakistan Limited, member of the Haleon Group ("Company") has lifted the event of force majeure declared on 21 October 2022 for the captioned range of products.

We appreciate the efforts of the Federal Government to revise the prices of Panadol Tablets, Panadol Extra Tablets and Children's Panadol Liquid Range, which will help the Company to continue to produce everyday healthcare products without gross losses. We are specifically grateful to the Prime Minister, Finance Minister, SAPM for Finance, Health Minister, Health Secretary, CEO DRAP and all other stakeholders in this regard.

Although the price revisions granted do not fully mirror the sharp increase in the raw material prices of Paracetamol, we have resumed production in the larger interest of consumers and patients in Pakistan. We look forward to further discussions and engagement with the Federal Government, in due course, to discuss our long-term strategy to provide better everyday health with humanity, and based on trusted science.

	Product			Current Price			Demanded Price			Agreed Price
			(Rs)			(Rs)			(Rs)
Panadol Plain Tabs 500 mg	1.87		2.67		2.35
Panadol Extra Tabs 500 mg	2.19		3.32		2.75
Children's Panadol Liquid	104.8		117.6		117.6

The Company resumed the full capacity manufacturing of Panadol Tablets, Panadol Extra Tablets and Children's Panadol Liquid Range once an agreement was reached with the key Federal Government's representatives.

We are grateful for the resolution of this matter and are hopeful for the continued support of all stakeholders to enable the Company to remain fully committed to deliver better everyday health with humanity.

1

Disclosure form in terms of Section 96 of the Securities Act 2015 is also attached for information.

You may please inform the TRE Certificate holders of the Exchange accordingly

Yours truly,

For and on Behalf of GlaxoSmithKline Consumer Healthcare Pakistan Limited (member of the Haleon Group)

Mr. Farhan Muhammad Haroon

Chief Executive Officer and General Manager

CC:

1. Principal Secretary, Office of the Prime Minister of Pakistan
2. Minister of NHS, Regulation & Coordination
3. Minister of Finance
4. Special Assistant to the Prime Minister on Finance
5. High Commissioner for the United Kingdom
6. Deputy High Commissioner for the United Kingdom
7. Secretary NHS, Regulation & Coordination
8. Chief Executive Officer, Drug Regulatory Authority of Pakistan
9. Director Costing & Pricing, Drug Regulatory Authority of Pakistan
10. Members of Drug Pricing Committee
11. Minister of Health, Government of Sindh
12. Minister of Health, Government of Punjab
13. Minister of Health, Government of KPK
14. Minister of Health, Government of Baluchistan
15. Minister of Health, Government of Gilgit Baltistan
16. Secretary Health, Government of Sindh
17. Secretary Health, Government of Punjab
18. Secretary Health, Government of KPK
19. Secretary Health, Government of Baluchistan
20. Secretary Health, Government of Gilgit Baltistan
21. Overseas Investors Chamber of Commerce & Industry (OICCI)
22. Pakistan Pharmaceutical Manufacturers Association
23. Executive Director / HOD, Offsite-II Department, Supervision Division, Securities and Exchange Commission of Pakistan, Islamabad.

2

		SCHEDULE
	DISCLOSURE FORM
Name of Company:	GlaxoSmithKline Consumer Healthcare Pakistan Limited
Registered Office	Sandoz Nagar, Petaro Road, Jamshoro Sindh, 76100.
Date of Report:	4 November 2022
Contact Information:	Farhan Muhammad Haroon
	Chief Executive Officer
	Telephone No.:	[phone]
	Fax No.:	N/A
	Email Address:	[e-mail]

Disclosure of price sensitive information by listed company in terms of Section 96 of the Securities Act 2015.

Please be notified that GlaxoSmithKline Consumer Healthcare Pakistan Limited, member of the Haleon Group ("Company") has lifted the event of force majeure declared on 21 October 2022 for the captioned range of products.

We appreciate the efforts of the Federal Government to revise the prices of Panadol Tablets, Panadol Extra Tablets and Children's Panadol Liquid Range, which will help the Company to continue to produce everyday healthcare products without gross losses. We are specifically grateful to the Prime Minister, Finance Minister, SAPM for Finance, Health Minister, Health Secretary, CEO DRAP and all other stakeholders in this regard.

Although the price revisions granted do not fully mirror the sharp increase in the raw material prices of Paracetamol, we have resumed production in the larger interest of consumers and patients in Pakistan. We look forward to further discussions and engagement with the Federal Government, in due course, to discuss our long-term strategy to provide better everyday health with humanity, and based on trusted science.

	Product			Current Price			Demanded Price			Agreed Price
			(Rs)			(Rs)			(Rs)
Panadol Plain Tabs 500 mg	1.87		2.67		2.35
Panadol Extra Tabs 500 mg	2.19		3.32		2.75
Children's Panadol Liquid	104.8		117.6		117.6

The Company resumed the full capacity manufacturing of Panadol Tablets, Panadol Extra Tablets and Children's Panadol Liquid Range once an agreement was reached with the key Federal Government's representatives.

We are grateful for the resolution of this matter and are hopeful for the continued support of all stakeholders to enable the Company to remain fully committed to deliver better everyday health with humanity.

For and on Behalf of GlaxoSmithKline Consumer Healthcare Pakistan Limited (member of the Haleon Group)

Mr. Farhan Muhammad Haroon

Chief Executive Officer and General Manager

3